CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NCT04318678 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

AML/MDS
B-ALL
T-ALL
BPDCN

Interventions

DRUG: CD123-CAR T
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna
DRUG: Rituximab

Sponsor

St. Jude Children's Research Hospital